While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...

NULISA employs a sequential immunocomplex capture and release technique to improve the sensitivity of traditional proximity ...

Faro Health Inc., the leading AI-powered platform for data-driven clinical protocol design, today announced it has partnered with Recursion (NASDAQ: RXRX) to accelerate and optimize clinical protocol ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

On the first day of the J.P. Morgan Healthcare Conference, drug executives talked M&A, but also sized up the prospects of ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Regenxbio, a prolific developer of gene therapy technology, will hand Japan’s Nippon Shinyaku certain rights to two ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...